Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cancer immunotherapeutics - PsiOxus Therapeutics

Drug Profile

Research programme: cancer immunotherapeutics - PsiOxus Therapeutics

Alternative Names: AbEnAds; anti-human VEGF armed EnAd; anti-PDL1 AbEnAds; NG 345; NG 347; NG 600; NG 641; NG aEpCAM; NG aFAP; NG-600 series

Latest Information Update: 15 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PsiOxus Therapeutics
  • Class Antibodies; Antineoplastics; Bispecific antibodies; Gene therapies; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; Epithelial cell adhesion molecule inhibitors; Fibroblast activation protein antagonists; Gene transference; Immunomodulators; Immunostimulants; Programmed cell death-1 ligand-1 inhibitors; Vascular endothelial growth factors modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 14 Aug 2019 PsiOxus Therapeutics plans a phase I trial of of NG 641 for Glandular and epithelial neoplasms (Metastatic disease, Late stage disease, Second line therapy or greater) in October 2019 (NCT04053283)
  • 15 May 2019 US FDA approves IND application for NG 641 in Cancer before May 2019 (PsiOxus pipeline, May 2019)
  • 29 Mar 2019 Pharmacodynamics data from preclinical studies in Cancer presented at the 110th Annual Meeting of the American Association for Cancer Research (AACR-2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top